Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
A phase II study of derdleukin diftitox (Ontak (R)) with CHOP chemotherapy in patients with newly-diagnosed aggressive T-cell lymphomas, the CONCEPT trial: Interim analysis. Foss, F. M., Sjak-Shie, N., Goy, A., Advani, R., Jacobsen, E., Acosta, M. AMER SOC HEMATOLOGY. 2006: 696A–697A
View details for Web of Science ID 000242440003251